US EditionPublished • loading... • Updated
Can 6-month long regimens become the standardized treatment for MDR-TB globally? - AMR Insights
Summary by AMR Insights
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Can 6-month long regimens become the standardized treatment for MDR-TB globally? - AMR Insights
This review discusses recent progress and remaining challenges in treating multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB). After decades of long, toxic regimens, the WHO now recommends two short 6-month treatments: BPaLM (2022) and BDLLfxC (2025). The newer BDLLfxC regimen—substituting delamanid for pretomanid—broadens eligibility to include children, adolescents, and pregnant or breastfeeding women, for whom BPaLM is unsuitable. Despit…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
